Anuradha Krishnamurthy, MBBS, provides backgrounds on TILs and discusses their critical role in the advanced melanoma treatment landscape.
2025
Podcast: Effectiveness and Cost-Effectiveness of Gene Panels in Melanoma
JCO PO author Dr. Dean A. Regier at the Academy of Translational Medicine, University of British Columbia (UBC), and the School of Population and Public Health, BC Cancer Research Institute shares insights into his JCO PO article, “Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation.”
Clinical Perspectives: Single-Agent Vs Combination Immunotherapy for Melanoma
Panelists discuss how monotherapy may still be appropriate for certain patient populations including those with desmoplastic melanoma, solid organ transplants, severe autoimmune disease, and older patients where the toxicity risk of combination therapy may outweigh benefits.
Who should be screened for skin cancer?
Skin cancer is the most common cancer in the U.S. More than 6 million adults are treated for it each year, says Dr. Michael Colgan, a Mayo Clinic Health System dermatologist in Eau Claire, Wisconsin.